SBEV vs GLTO Comparison

Splash Beverage Group Inc is a portfolio company managing multiple brands across several growth segments within the consumer beverage industry. The company's two reportable operating segments are: (1) the manufacture and distribution of non-alcoholic and alcoholic beverages, and (2) the retail sale of beverages and groceries online. The company generates the majority of its revenue from the E-Commerce segment. Qplash is a wholly owned division of Splash. It is the company's first entry point into the e-commerce channel. For beverage-alcohol products, the company operate within what is referred to as a "Three Tier Distribution System" where manufacturers are not permitted to sell directly to retailers, but instead, contract for local and regional distribution with independent distributors.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.